

# Andrew J Ullmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6315453/publications.pdf>

Version: 2024-02-01

31  
papers

7,446  
citations

279798

23  
h-index

414414

32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

5521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
2	Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells. <i>Medical Mycology</i> , 2019, 58, 187-196.	0.7	7
3	Susceptibility of <i>A. fumigatus</i> -specific T-cell assays to pre-analytic blood storage and <i>scp</i> -PBMC cryopreservation greatly depends on readout platform and analytes. <i>Mycoses</i> , 2018, 61, 549-560.	4.0	13
4	Analysis of the in vitro activity of human neutrophils against <i>Aspergillus fumigatus</i> in presence of antifungal and immunosuppressive agents. <i>Medical Mycology</i> , 2018, 56, 514-519.	0.7	3
5	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207.	1.8	162
6	Evaluation of <i>Aspergillus</i> and <i>Mucorales</i> specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure. <i>International Journal of Medical Microbiology</i> , 2018, 308, 1018-1026.	3.6	13
7	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. <i>Mycoses</i> , 2018, 61, 868-876.	4.0	9
8	Comparative Analysis of Inflammatory Cytokine Release and Alveolar Epithelial Barrier Invasion in a Transwell® Bilayer Model of Mucormycosis. <i>Frontiers in Microbiology</i> , 2018, 9, 3204.	3.5	13
9	Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3406-3413.	3.0	58
10	Intra- and inter-individual variability of <i>Aspergillus fumigatus</i> reactive T-cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment. <i>Mycoses</i> , 2017, 60, 668-675.	4.0	12
11	Position paper on current aspects of sponsoring in accredited CME. <i>Journal of European CME</i> , 2017, 6, 1312062.	1.6	4
12	<i>Mucorales</i> spores induce a proinflammatory cytokine response in human mononuclear phagocytes and harbor no rodlet hydrophobins. <i>Virulence</i> , 2017, 8, 1708-1718.	4.4	25
13	Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive <i>Aspergillus</i> infections. <i>Mycoses</i> , 2016, 59, 480-493.	4.0	19
14	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. <i>Annals of Hematology</i> , 2016, 95, 1435-1455.	1.8	169
15	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet</i> , The, 2016, 387, 760-769.	13.7	695
16	Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2078-2085.	3.2	99
17	Clinical-scale isolation of the total <i>Aspergillus fumigatus</i> reactive helper cell repertoire for adoptive transfer. <i>Cytotherapy</i> , 2015, 17, 1396-1405.	0.7	30
18	Letemovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2014, 370, 1781-1789.	27.0	315

#	ARTICLE	IF	CITATIONS
19	Treatment of invasive fungal infections in cancer patientsâ€™ updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014, 93, 13-32.	1.8	143
20	Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3610-3617.	3.2	79
21	Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. <i>Haematologica</i> , 2010, 95, 1762-1768.	3.5	121
22	Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWPO1 trial. <i>Vaccine</i> , 2010, 28, 2730-2734.	3.8	66
23	Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2009, 48, 1392-1401.	5.8	110
24	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). <i>Clinical Infectious Diseases</i> , 2007, 44, 1289-1297.	5.8	663
25	Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. <i>New England Journal of Medicine</i> , 2007, 356, 348-359.	27.0	1,613
26	Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2007, 356, 335-347.	27.0	1,228
27	Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease. <i>Pharmacotherapy</i> , 2007, 27, 1627-1636.	2.6	163
28	Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2006, 42, 1726-1734.	5.8	198
29	Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. <i>Clinical Infectious Diseases</i> , 2006, 43, e29-e38.	5.8	100
30	Early Detection of Toxoplasma Infection by Molecular Monitoring of Toxoplasma gondii in Peripheral Blood Samples after Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 40, 67-78.	5.8	221
31	Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies. <i>Annals of Hematology</i> , 2003, 82, S175-S185.	1.8	77